Update on US Food and Drug Administration Emergency Use Authorisation of Evusheld
26 January 2023 -- The US Food and Drug Administration (FDA) has stated that AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab) is not currently authorised for Emergency Use for pre-exposure prophylaxis (prevention) of COVID-19... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 26, 2023 Category: Pharmaceuticals Source Type: clinical trials
c-Abl Demonstrates Potential as a Key Therapeutic Target in Parkinson's Disease and Related Disorders
BOSTON and ATLANTA, Jan. 25, 2023. Inhibikase Therapeutics, Inc. ( " Inhibikase " or " Company " ), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson ' s disease, Parkinson ' s-related... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 25, 2023 Category: Pharmaceuticals Source Type: clinical trials
Health Canada Approval of Phase 2 Clinical Trial with Low-Dose Psilocybin
TORONTO, Jan. 24, 2023. Diamond Therapeutics Inc. ( " Diamond " ), a drug development company focused on low-dose psychedelic-derived therapies for use in the treatment of mental health, is pleased to announce it has received Health Canada approval to... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 24, 2023 Category: Pharmaceuticals Source Type: clinical trials
Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program
HAYWARD, Calif., Jan. 23, 2023. Benitec Biopharma Inc. (“Benitec” or“the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 23, 2023 Category: Pharmaceuticals Source Type: clinical trials
Overdose Deaths Involving Buprenorphine Did Not Proportionally Increase With New Flexibilities in Prescribing
January 20, 2023 -- The proportion of opioid overdose deaths involving buprenorphine, a medication used to treat opioid use disorder, did not increase in the months after prescribing flexibilities were put in place during the COVID-19 pandemic,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 20, 2023 Category: Pharmaceuticals Source Type: clinical trials
Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease
TOKYO, Jan. 20, 2023. Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., " Astellas " ) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on January 19th for the FORTIS Ph1/2 clinical... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 20, 2023 Category: Pharmaceuticals Source Type: clinical trials
U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab
Accelerated approval application was based on Phase 2 trial showing amyloid plaque lowering
Complete response letter based on limited number of patients with 12-month drug exposure data in the accelerated approval submission; no other... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 19, 2023 Category: Pharmaceuticals Source Type: clinical trials
Apex Labs Granted Approval for 294 Patient Take Home Psilocybin Clinical Trial
VANCOUVER, BC, Jan. 19, 2023. Apex Labs Ltd. (APEX or the Company), a pharmaceutical company optimizing the standard of mental health care with psilocybin, is pleased to announce its approval by Health Canada to begin APEX-002-A01-03, the world ' s... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 19, 2023 Category: Pharmaceuticals Source Type: clinical trials
Induced Physiological Ketosis in Asthenia and\or Decreased Tolerance to Physical and\or Mental Exertion
Condition: Patient Activation Intervention: Dietary Supplement: PanTrek Sponsor: Ketonic Pharm LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 19, 2023 Category: Research Source Type: clinical trials
